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1. INTRODUCTION {#brb31315-sec-0005}
===============

Epilepsy during pregnancy poses a special challenge to neurologists worldwide. The treatment must balance the risk of seizures with the potential for adverse effects from drug use which may affect both the mother and developing fetus (Bech et al., [2014](#brb31315-bib-0002){ref-type="ref"}; Cohen‐Israel et al., [2018](#brb31315-bib-0004){ref-type="ref"}; Vajda et al., [2017](#brb31315-bib-0019){ref-type="ref"}). Lamotrigine (LTG) is a second‐generation antiepileptic drug (AED) with broad spectrum activity. It is considered an ideal AED administered to women of childbearing age and during pregnancy (Yasam et al., [2016](#brb31315-bib-0021){ref-type="ref"}). Previous studies have reported that the pharmacokinetics of LTG are substantially affected by pregnancy (Fotopoulou et al., [2009](#brb31315-bib-0007){ref-type="ref"}; Milosheska et al., [2016](#brb31315-bib-0009){ref-type="ref"}; Pennell et al., [2004](#brb31315-bib-0010){ref-type="ref"}, [2008](#brb31315-bib-0011){ref-type="ref"}; Polepally et al., [2014](#brb31315-bib-0014){ref-type="ref"}; Reisinger, Newman, Loring, Pennell, & Meador, [2013](#brb31315-bib-0015){ref-type="ref"}), so a dose adjustment may be needed under therapeutic drug monitoring (TDM) during pregnancy. However, there is a lack of Chinese data until now, regardless of the sample size. The aims of the present study were to evaluate the pharmacokinetic changes in LTG from prepregnancy to postpartum and to assess the impact of TDM on seizure management during pregnancy in a Chinese population.

2. METHODS {#brb31315-sec-0006}
==========

2.1. Patient characteristics {#brb31315-sec-0007}
----------------------------

Women who were pregnant or planning pregnancy and who suffered from epilepsy and were treated with LTG during January 2014--April 2018 at Shengjing Hospital, China Medical University were screened for inclusion in the present retrospective study. All patients met the criteria for the diagnosis of epilepsy issued by the International League against Epilepsy in 2017 (Scheffer et al., [2017](#brb31315-bib-0018){ref-type="ref"}) and received LTG monotherapy. Patients were excluded for age \<17 years, cardiopulmonary dysfunction, renal or hepatic dysfunction, significant mental retardation (IQ \<70), depression, schizophrenia, or other serious mental disorders, and coadministration of medications known to influence the pregnancy outcome. Patients on an AED polytherapy regimen that could contribute to seizure control were excluded. All subjects received no concomitant drugs interacting with LTG before or after pregnancy, including enzyme‐inducing antiepileptic drugs, estrogen‐containing contraceptives, or antipsychotic drug such as sertraline. This study was approved by the Ethics Committee for Clinical Trials of Shengjing Hospital (no. 2018PS417K).

Age of delivery, onset age of epilepsy, gestational age (GA) at birth, sex and birth weight of the fetus, seizure type, changes in the frequency of epileptic seizures during pregnancy compared with 1 year before pregnancy, LTG serum concentrations (before conception, during pregnancy, and postpartum), LTG dose, and health status of the fetus were collected. GA was determined based on last menstrual period. The LTG serum concentration was then classified as preconception, first trimester (≤13 weeks GA), second trimester (14--27 weeks GA), third trimester (≥28 weeks GA--delivery), or postpartum. Blood samples were taken before the morning dose, which was at least 6 hr after the last dose. The LTG dosage was adjusted according to the patients\' seizure type, seizure frequency, and individual target concentrations. The target serum concentration for each patient is the ideal concentration at which seizures are well controlled without adverse effects (Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}). Results of the LTG serum concentrations were actively used for TDM to maintain stable levels throughout pregnancy. The laboratory analysis was performed by high‐pressure liquid chromatography. As LTG presents only moderate protein binding capacity, we determined the total concentration values (Clark, Klein, Perel, Helsel, & Wisner, [2013](#brb31315-bib-0003){ref-type="ref"}; Fotopoulou et al., [2009](#brb31315-bib-0007){ref-type="ref"}; Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}). The formula for calculating apparent clearance (AC) was: AC (mg/\[mg/L\]) = daily dose (mg)/serum concentration (mg/L) (Pennell et al., [2004](#brb31315-bib-0010){ref-type="ref"}). Prepregnancy target LTG serum concentrations and baseline seizure frequencies were collected from the patients to assess the association between LTG serum concentration and seizure frequency. We also calculated the ratio of LTG concentration to individual target concentration (RTC). These values were calculated for each trimester and for each month. A receiver operating characteristic (ROC) curve was drawn to determine the threshold of RTC and to predict the increased seizure frequency.

2.2. Statistical analyses {#brb31315-sec-0008}
-------------------------

The statistical analyses (descriptive statistics, *t* test, chi‐square test, and ROC curve) were conducted with IBM SPSS Statistics Version 19.0 (IBM Corp., Armonk, NY). A *p* \< 0.05 was considered significant.

3. RESULTS {#brb31315-sec-0009}
==========

A total of 12 patients and their 12 pregnancies were included (Table [1](#brb31315-tbl-0001){ref-type="table"}). The mean age of delivery was (28.6 ± 5.4) years (range, 20--41 years). No premature births or deformities were detected. Of the 12 patients, five (41.7%) had no seizures during pregnancy and seven (58.3%) had seizures. There was a significant difference in seizures between the first and the second trimester (*p* = 0.0304), but no significant difference between the second and the third trimester (*p* = 0.0917).

###### 

Study population characteristics

  Patient number   Pregnancy number   Age of delivery (year)   Age of epilepsy onset (year)   Gestational age at birth (week)   Dose used prior to pregnancy (mg)   Target concentration (mg/L)   Birth weight of fetus (g)   Sex of fetus   Apgar score of fetus   Seizure types before pregnancy   Types and numbers of seizures in                
  ---------------- ------------------ ------------------------ ------------------------------ --------------------------------- ----------------------------------- ----------------------------- --------------------------- -------------- ---------------------- -------------------------------- ---------------------------------- ------------ ------
  1                1                  41                       8                              39                                ---                                 ---                           3,100                       F              10                     FIA                              ---                                FIA1         ---
  2                2                  30                       16                             38                                150                                 2.73                          3,300                       F              10                     GTC, FIA                         FIA1                               FIA3         ---
  3                3                  27                       16                             38                                ---                                 ---                           3,600                       M              10                     GTC, FIA                         ---                                FIA2         FIA3
  4                4                  22                       14                             38                                100                                 2.72                          3,400                       M              10                     GTC, FIA                         ---                                GTC3, FIA1   ---
  5                5                  26                       12                             38                                50                                  1.80                          2,700                       F              10                     GTC                              ---                                ---          ---
  6                6                  30                       10                             38                                ---                                 ---                           2,850                       F              10                     GTC                              ---                                ---          ---
  7                7                  30                       1                              39                                75                                  1.43                          3,000                       M              10                     GTC                              ---                                GTC2         ---
  8                8                  20                       10                             37                                50                                  1.90                          3,000                       F              10                     GTC, FIA                         ---                                FIA2         ---
  9                9                  33                       14                             39                                100                                 3.18                          3,400                       F              10                     GTC                              ---                                ---          ---
  10               10                 28                       10                             37                                ---                                 ---                           3,050                       M              10                     GTC                              ---                                ---          ---
  11               11                 26                       18                             39                                ---                                 ---                           3,300                       F              10                     GTC                              ---                                ---          ---
  12               12                 30                       24                             40                                125                                 2.33                          3,570                       M              10                     GTC, FIA                         ---                                GTC1         GTC1

The number behind represents the number of seizure attacks.

Abbreviations: FIA, focal impaired awareness; GTC, generalized tonic--clonic seizure.

χ^2^ test for seizures between the first and the second trimesters (*p* = 0.0304), χ^2^ test for seizures between the second and the third trimester (*p* = 0.0917).

John Wiley & Sons, Ltd

The AC of LTG across the pregnancy and postpartum periods showed individual differences (Figure [1](#brb31315-fig-0001){ref-type="fig"}). A large variation in AC values was observed among the patients. Compared with the prepregnancy level, AC increased by 82.5% during the first trimester (*p* = 0.0343), 203.2% during the second trimester (*p* = 0.0010), and by 197.0% during the third trimester (*p* = 0.0061). After delivery, the value returned to the prepregnancy level (Table [2](#brb31315-tbl-0002){ref-type="table"}).

![Individual changes in AC from prepregnancy to postpartum. AC, apparent clearance; N, patient number; TM1, TM2, TM3, first, second, and third trimester, respectively; PP1M, PP2M, first and second month postpartum, respectively; PreP, prepregnancy values](BRB3-9-e01315-g001){#brb31315-fig-0001}

###### 

Mean AC values

  Stages of pregnancy   Mean AC (mg/\[mg/L\])   Percentage changes[a](#brb31315-note-0006){ref-type="fn"}   *SD*   Number of patients   Number of samples   *p*‐value
  --------------------- ----------------------- ----------------------------------------------------------- ------ -------------------- ------------------- -----------
  Prepregnancy          40.5                                                                                12.8   7                    7                    
  1st trimester         73.9                    82.5                                                        36.1   10                   13                  0.0343
  2nd trimester         122.8                   203.2                                                       53.2   12                   25                  0.0010
  3rd trimester         120.3                   197.0                                                       66.0   12                   28                  0.0061
  PP1M                  83.6                    106.4                                                       55.9   8                    8                   0.0683
  PP2M                  33.6                    −17.0                                                       17.6   5                    5                   0.4495

Abbreviations: AC, apparent clearance; PP1M, PP2M, first and second month postpartum, respectively; *SD*, standard deviation.

Percentage change compared with values before pregnancy.

John Wiley & Sons, Ltd

Seven patients (nos. 2, 4, 5, 7, 8, 9, and 12), who had adequate baseline information about prepregnancy target serum concentrations and seizure frequencies, were included to examine the association between LTG serum concentration and seizure frequency (Table [3](#brb31315-tbl-0003){ref-type="table"}).

###### 

Percentages of patients with increased seizure frequency compared with the prepregnancy baseline by gestational age and months postpartum

  Month          1   2   3      4      5      6      7      8   9      10   PP1   PP2
  -------------- --- --- ------ ------ ------ ------ ------ --- ------ ---- ----- -----
  Patients (%)   0   0   14.3   28.6   57.1   14.3   28.6   0   14.3   0    0     0

John Wiley & Sons, Ltd

The percentage of patients who had an increase in seizures is plotted in Figure [2](#brb31315-fig-0002){ref-type="fig"}, along with the AC by month. Increased seizure frequency occurred in the highest percentage of patients during the fifth month of pregnancy (57.1%).

![The AC of LTG and increased seizures during pregnancy and postpartum period. Mean (±*SE*) AC and percentage of patients with increased seizure frequency compared with prepregnancy baseline, by month gestational age and month postpartum. AC, apparent clearance; LTG, lamotrigine; M, month](BRB3-9-e01315-g002){#brb31315-fig-0002}

Forty‐eight RTC values were calculated. We performed the *t* test to compare the RTC values of patients who had an increased seizure frequency with the RTC values of those who did not. The RTC values of these two groups were significantly different (*p* = 0.0164), and increased seizure frequency was associated with a lower RTC. We drew the ROC curve for predicting increased seizure frequency with reference to Pennell et al. ([2008](#brb31315-bib-0011){ref-type="ref"}), and calculated the RTC threshold that best predicted an increase of seizure frequency (Figure [3](#brb31315-fig-0003){ref-type="fig"}). A reduction in the RTC below the threshold was viewed as increased susceptibility to seizures. When the RTC threshold = 64.34%, a true‐positive rate of 90.91% and a true‐negative rate of 51.35% were achieved.

![ROC curve of the RTC threshold for predicting increased seizure frequency. AUC = 0.749, 95% CI: (0.603--0.863), *p*‐value: 0.0013. AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic; RTC, ratio of LTG concentration to target concentration](BRB3-9-e01315-g003){#brb31315-fig-0003}

4. DISCUSSION {#brb31315-sec-0010}
=============

Lamotrigine is considered an ideal AED for pregnant women because of its effectiveness in treating epilepsy and the low risk of fetal malformations and altered cognitive development. LTG exposure carries the lowest risk for overall malformations based on current evidence (Weston et al., [2016](#brb31315-bib-0020){ref-type="ref"}). Exposure to LTG does not have detrimental effect on child neurodevelopment (Cummings, Stewart, Stevenson, Morrow, & Nelson, [2011](#brb31315-bib-0005){ref-type="ref"}). Longer term studies find no significant effect of lamotrigine on IQ at age 6 years (Baker et al., [2015](#brb31315-bib-0001){ref-type="ref"}; Cohen‐Israel et al., [2018](#brb31315-bib-0004){ref-type="ref"}). No premature births or deformities were detected in this study. Long‐term follow‐up is required to assess cognitive impairment.

Pregnancy influences the pharmacokinetics of LTG. This study confirmed previous reports of significant increases in clearance between preconception baseline and all trimesters of pregnancy. Whether there is a difference in LTG clearance change across racial groups is inconclusive. In a retrospective analysis of 95 pregnant women with epilepsy of which 69 pregnancies were controlled by LTG, Reisinger et al., ([2013](#brb31315-bib-0015){ref-type="ref"}) found no difference between Caucasian, African American, and Asian patients in clearance change for all drugs combined or for LTG monotherapy. In another prospective study of 53 women treated with LTG monotherapy, Pennell et al found a difference in free LTG clearance between white and black patients, with the white patients exhibiting a higher clearance. But this trend was not observed for total LTG clearance (Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}). In this study, the extent of change in clearance was in the middle of the range compared with previous studies (Fotopoulou et al., [2009](#brb31315-bib-0007){ref-type="ref"}; Milosheska et al., [2016](#brb31315-bib-0009){ref-type="ref"}; Pennell et al., [2004](#brb31315-bib-0010){ref-type="ref"}, [2008](#brb31315-bib-0011){ref-type="ref"}; Polepally et al., [2014](#brb31315-bib-0014){ref-type="ref"}; Reisinger et al., [2013](#brb31315-bib-0015){ref-type="ref"}). In a larger US‐based cohort study, the majority (77%) of women had a substantial increase in the oral clearance by the end of pregnancy, whereas 23% of women had a minimal increase (Polepally et al., [2014](#brb31315-bib-0014){ref-type="ref"}). We could not look for this because of our small sample size. But when we view Figure [1](#brb31315-fig-0001){ref-type="fig"}, it does appear that our cohort could also fall into different subpopulations with N4 in the high clearance change group and N9 in the low clearance change group.

At present, TDM may not be fully and correctly utilized. Some studies indicate that LTG dose changes were often not guided by TDM (Richards, Reith, Stitely, & Smith, [2018](#brb31315-bib-0016){ref-type="ref"}). The effectiveness of TDM and serum LTG during pregnancy for improving seizure control has been demonstrated (Fotopoulou et al., [2009](#brb31315-bib-0007){ref-type="ref"}; de Haan et al., [2004](#brb31315-bib-0006){ref-type="ref"}; Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}; Petrenaite, Sabers, & Hansen‐Schwartz, [2005](#brb31315-bib-0012){ref-type="ref"}; Pirie et al., [2014](#brb31315-bib-0013){ref-type="ref"}; Sabers, [2012](#brb31315-bib-0017){ref-type="ref"}). No uniform standard exists on how to use TDM during pregnancy. Also, there are no specific guidelines for monitoring frequency and duration of pregnancy. Some adjustments have been based entirely on serum concentrations (Sabers, [2012](#brb31315-bib-0017){ref-type="ref"}), while others had reference to clinical manifestations (Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}). The frequency of monitoring mentioned in previous reports was from once every 3 months (Petrenaite et al., [2005](#brb31315-bib-0012){ref-type="ref"}) to once every 1--3 months (Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}) to once every 4 weeks (Fotopoulou et al., [2009](#brb31315-bib-0007){ref-type="ref"}; Sabers, [2012](#brb31315-bib-0017){ref-type="ref"}). The monitoring frequency of this study was once every 1--3 months. Recent studies show that increases in LTG clearance can begin as early as 5 weeks GA, often before women know they are pregnant (Karanam et al., [2018](#brb31315-bib-0008){ref-type="ref"}). Many doctors and patients in China have not paid sufficient attention to TDM during pregnancy, leading to missing baseline or early concentrations. Our study confirms that planning of pregnancy is necessary and we should employ TDM as early as possible even before pregnancy and in the first month of GA. Specific data such as maternal weight, GA, LTG dose, time interval since the last dose, seizure types, seizure frequencies, and side effects should be recorded at every visit.

A reduction in RTC led to worsening seizures in this study. An RTC \< 0.64 was a predictor of deteriorating seizures. A dosage adjustment is necessary for women with epilepsy on LTG monotherapy during pregnancy when the LTG serum concentration is \<64% of the target concentration. Coincidentally, the threshold is close to previous reports (Pennell et al., [2008](#brb31315-bib-0011){ref-type="ref"}; Reisinger et al., [2013](#brb31315-bib-0015){ref-type="ref"}).

Some limitations of this study include partial loss of prepregnancy data, such as some weight and baseline serum concentrations. Additionally, we did not include weights in the clearance calculations, because patient weights were not available at some time points. However, AC also makes sense so that some studies adopted this variable (Pennell et al., [2004](#brb31315-bib-0010){ref-type="ref"}). In addition to AC, some studies used a ratio of serum concentration to daily dose (serum concentration/daily dose, \[mg/L\]/mg) to measure the changes in pharmacokinetics (de Haan et al., [2004](#brb31315-bib-0006){ref-type="ref"}; Petrenaite et al., [2005](#brb31315-bib-0012){ref-type="ref"}), regardless of body weight. Correspondingly, the ratio decreased during pregnancy compared with that before pregnancy. The study is also limited by the small sample size. We need to expand the sample size for further research. However, even these small numbers represent an addition to the Chinese data literature.

5. CONCLUSIONS {#brb31315-sec-0011}
==============

The pharmacokinetic changes in LTG during pregnancy displayed marked interpatient variation in this retrospective study. TDM can support a rational treatment plan for LTG use during pregnancy. We recommend regular monitoring of LTG serum concentrations from prepregnancy to postpartum. As TDM for pregnancy starts relatively late in China, both doctors and patients should pay more attention. Improving patient compliance is indispensable. Further effort is needed to develop dose adjustment regimes and treatment paradigms.
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